COVID-19 is an emerging, rapidly evolving situation. Public health information (CDC) Research information (NIH) SARS-CoV-2 data (NCBI) Prevention and treatment information (HHS)

FULL TEXT LINKS



 Review
 Drug Discov Today Technol. 2017 Jun;24:19-24. doi: 10.1016/j.ddtec.2017.10.003.

 Epub 2017 Oct 28.

## Novel approaches to targeting BRD4

Olesya A Kharenko<sup>1</sup>, Henrik C Hansen<sup>2</sup>

Affiliations PMID: 29233295 DOI: 10.1016/j.ddtec.2017.10.003

## Abstract

Inhibition of bromo and extra-terminal (BET) bromodomains, including BRD4, has emerged as a new exciting epigenetic target for oncology, in particular. Recently, novel alternatives to the traditional use of reversible small molecules have emerged, including proteolytic targeting BET agents and irreversible binding inhibitors. These alternatives to reversible inhibitors may offer some advantage and can be used as tools to further decipher the underlying biology. Supportive pre-clinical data have these novel approaches bound for clinical development in the near future.

Copyright © 2017 Elsevier Ltd. All rights reserved.

## LinkOut - more resources

**Full Text Sources** 

**Elsevier Science** 

Other Literature Sources The Lens - Patent Citations scite Smart Citations